Impact of COVID-19 on Business Activities and Business Plans
First written in FY2020. 3 of 11 entries say "Worsened", first in FY2021-Q2. Latest entry: FY2025.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2025RestatedAnnual report
「If business activities are subject to any restrictions or requests due to infectious diseases such as COVID-19, planned businesses may be delayed. If the impact is prolonged or an unforeseen event occurs due to a natural disaster, the performance and financial condition of the group may be affected.」
The company continued to disclose the risks of restrictions on business activities and delays to plans due to infectious diseases and natural disasters. - FY2024ReframedAnnual report
「If business activities are subject to any restrictions or requests due to infectious diseases such as COVID-19, planned businesses may be delayed. If the impact is prolonged or an unforeseen event occurs due to a natural disaster, the performance and financial condition of the group may be affected.」
The company classified COVID-19-related risks as risks of restrictions on business activities, including infectious diseases generally and natural disasters. - FY2022RestatedAnnual report
「While increasing the proportion of subscription services, a stock-based business, to secure stable revenue and conducting online business meetings and seminars as points of contact with customers, the company stated that depending on the spread of COVID-19, sales activities with customers could become limited and affect revenue in the short term.」
The company continued to disclose the risk that COVID-19 could restrict sales activities, while citing a higher subscription ratio and online business meetings and seminars as measures to address it. - FY2022-Q3MitigatedAnnual report
「In the same period of the previous year, sales activities with medical institutions were restricted by the impact of COVID-19, resulting in lower revenue and profit. In the current period, however, restrictions on sales activities were eased, and rising demand at hospitals to improve the productivity of doctors, nurses and other medical professionals supported strong sales of the company's core product, the AmiVoice® Ex7 series of AI voice-input software, resulting in higher revenue and profit year on year.」
Restrictions on sales activities due to COVID-19 were eased in the medical field, and the disclosure reported strong sales of the Ex7 series and higher revenue and profit. Although the impact remained, its business impact had decreased from the previous quarter. quantified was false, and materialized was true. - FY2022-Q2MitigatedAnnual report
「In the second quarter under review, sales activities were affected in part by declarations of a state of emergency due to COVID-19 and other factors. However, as the company promoted work-style reforms and responded to rising demand for AI speech recognition in line with new business practices arising from COVID-19, subscription revenue increased in BSR1 (the first growth engine). The resulting higher proportion of stock-based business improved the gross profit margin, enabling Advanced Media, on a standalone basis, to achieve a substantial increase in operating profit.」
Although some impact on sales activities remained due to declarations of a state of emergency and other factors, standalone operating profit increased substantially as demand for AI speech recognition and subscription revenue grew and the stock-based business ratio rose. - FY2022-Q1MitigatedAnnual report
「In the first quarter under review, sales activities were affected in part by declarations of a state of emergency due to COVID-19 and other factors. However, the effects of embedding subscription services, a stock-based business under BSR1 (the first growth engine), which the company had been pursuing, began to emerge, enabling it to achieve higher revenue and profit.」
Although the impact on sales activities remained, the effects of subscription services emerged, resulting in higher revenue and profit overall. - FY2021WorsenedAnnual report
「However, although revenue increased 1.6% year on year, profit declined due in part to restrictions on sales activities with medical institutions resulting from the impact of COVID-19.」
Restrictions on sales activities due to COVID-19 also affected full-year performance, becoming a specific factor behind the decline in profit in the Medical Division. - FY2021-Q3WorsenedAnnual report
「However, sales activities were restricted due to the impact of COVID-19, while some customers took a more cautious stance toward systems investment, among other factors, and performance remained below the initial plan.」
In addition to restrictions on sales activities due to COVID-19, customers continued to take a cautious stance toward systems investment, and performance was confirmed to be below the initial plan. - FY2021-Q2WorsenedAnnual report
「However, customer interactions declined and sales activities did not proceed as planned due to the impact of COVID-19, resulting in some delays in orders and deliveries.」
The impact of COVID-19 continued and became more concrete in the form of fewer customer interactions, delays in sales activities, and some delays in orders and deliveries. - FY2021-Q1MaterialisedAnnual report
「However, customer interactions became limited and some sales activities stagnated following the declaration of a state of emergency due to COVID-19, among other factors.」
The impact of COVID-19 on sales activities disclosed in the previous fiscal year materialized, resulting in limited customer interactions and some stagnation in sales activities. The disclosure also noted a decline in revenue in the Medical Division and an 8.0% year-on-year decrease in total revenue. - FY2020First statedAnnual report
「From the perspective of preventing the spread of COVID-19, sales activities targeting customers have become limited, which may affect revenue in the short term.」
The company disclosed restrictions on sales activities, delays to business plans, and potential impacts on business performance and financial condition from COVID-19 as new risks. As of the filing date, it stated that there had been no material impact.